@article {7784,
	title = {Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial},
	journal = {Journal of Clinical Oncology},
	volume = {28},
	year = {2010},
	note = {Cited By :249Export Date: 21 February 2017},
	month = {2010},
	pages = {2259 - 2266},
	abstract = {Purpose: The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up, and evaluate the impact of subsequent therapies. Patients and Methods: Previously untreated symptomatic patients with myeloma ineligible for high-dose therapy received up to nine 6-week cycles of VMP (n = 344) or MP (n = 338). Results: With a median follow-up of 36.7 months, there was a 35\% reduced risk of death with VMP versus MP (hazard ratio, 0.653; P < .001); median OS was not reached with VMP versus 43 months with MP; 3-year OS rates were 68.5\% versus 54.0\%. Response rates to subsequent thalidomide-(41\% v 53\%) and lenalidomide-based therapies (59\% v 52\%) appeared similar after VMP or MP; response rates to subsequent bortezomib-based therapy were 47\% versus 59\%. Among patients treated with VMP (n = 178) and MP (n = 233), median survival from start of subsequent therapy was 30.2 and 21.9 months, respectively, and there was no difference in survival from salvage among patients who received subsequent bortezomib, thalidomide, or lenalidomide. Rates of adverse events were higher with VMP versus MP during cycles 1 to 4, but similar during cycles 5 to 9. With VMP, 79\% of peripheral neuropathy events improved within a median of 1.9 months; 60\% completely resolved within a median of 5.7 months. Conclusion: VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy. First-line bortezomib use does not induce more resistant relapse. VMP used upfront appears more beneficial than first treating with conventional agents and saving bortezomib- and other novel agent-based treatment until relapse. {\textcopyright} 2010 by American Society of Clinical Oncology.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-77952310929\&doi=10.1200\%2fJCO.2009.26.0638\&partnerID=40\&md5=3a06900c70c560408123e42800375878},
	author = {Mateos, M.-V. and Richardson, P.G. and Schlag, R. and Khuageva, N.K. and Dimopoulos, M.A. and Shpilberg, O. and Kropff, M. and Spicka, I. and Petrucci, M.T. and Palumbo, A. and Samoilova, O.S. and Dmoszynska, A. and Abdulkadyrov, K.M. and Schots, R. and Jiang, B. and Esseltine, D.L. and Liu, K. and Cakana, A. and van de Velde, H. and San Miguel, J.F.}
}
